Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

Researchers conducted this study to determine how often and why spontaneous soft drusen regresses without atrophy in patients who had intermediate or atrophic age-related macular degeneration.

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.

Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.

Catch up on this week's highlights in retina.

OCT-A angiography can help reveal early neurodegenerative disease signs, offering a noninvasive method for identifying high-risk patients through retinal analysis.

The presence of AMD predicted an increased risk of all-cause and CVD mortality in patients with a high risk of CVD, even in the early stages of AMD.

Sanofi's gene therapy SAR402663 receives FDA fast track designation, targeting neovascular age-related macular degeneration with positive clinical trial data.

Findings from the retrospective, observational study support the potential anti-inflammatory benefits of the drug class.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

A study reveals similar risks of sight-threatening diabetic retinopathy in pregnant women with type 1 diabetes compared with nonpregnant controls.

The acquisition includes the noninvasive Valeda PBM device for the treatment of early and intermediate dry age-related macular degeneration.

Recent research highlights inferred sensitivity mapping as a promising method to assess retinal function in geographic atrophy, enhancing clinical trial outcomes.

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa.

In the debut episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Tony Stefater, MD, PhD; and Tommy Stryjewski, MD, about PYK-2101, a biodegradable retinal sealant designed to replace gas and oil tamponades.

Alfredo Sadun, MD, PhD, details an unexpected outcome from a gene therapy in development for Leber hereditary optic neuropathy (LHON).

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).

A study reveals that ophthalmic artery angioplasty improves vision and functionality in patients with late-stage age-related macular degeneration.

Prof Tunde Peto and Prof Catherine Creuzot-Garcher will serve on an educational panel during the networking event.

Neurotech Pharmaceuticals enhances its leadership by appointing Peter J. McDonnell, MD, a leading ophthalmology expert, to its Board of Directors.

An understanding of GA growth kinetics is key to addressing the pathophysiology of age-related macular degeneration.

Roche's Contivue platform gains EU CE mark, offering innovative treatment for neovascular AMD with fewer injections and promising long-term vision outcomes.

Prithvi Ramtohul, MD, is a PhD candidate based in Marseille, France and previously completed a fellowship in Paris under Prof. Tadayoni.